Company news
Orum Therapeutics, Inc. (KRX:475830) news
Orum Therapeutics, Inc. news releases on 6ix. Latest, Aug 23, 2026: Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel…
Press releases & updates
Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
August 22, 2026
Orum Therapeutics Appoints Dr. Maria Koehler and Geoff Meyerson to Board of Directors
April 13, 2026
Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR Annual Meeting 2026
March 17, 2026
Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153 at the 2025 American Society of Hematology (ASH) Annual Meeting
November 3, 2025
Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orum’s Degrader–Antibody Conjugate Payload Platforms and Expand TPD²® Therapeutic Applications
October 14, 2025